Key Highlights
- Eric Perreault promoted to CEO, succeeding co-founder Matt Gevaert, PhD.
- Focused on revolutionizing cancer care with KIYA-Predict™ and 3D Predict™ platforms.
- Company aims for transformative change in functional precision oncology and patient outcomes.
Source: Business Wire
Notable Quotes
- “We’re confident that, under Eric’s guidance, Kiyatec will make a meaningful and enduring contribution to cancer treatment and drug discovery,” – Matt Gevaert, Co-Founder at Kiyatec
- “In my new role as CEO, my mission is to drive Kiyatec toward truly revolutionizing cancer care,” – Eric Perreault, CEO at Kiyatec
SoH's Take
The appointment of Eric Perreault as CEO of Kiyatec marks a pivotal moment for the company, signaling a renewed commitment to pioneering advancements in cancer treatment through its functional precision medicine approach. His extensive experience and leadership are poised to steer Kiyatec into a new era of growth and innovation, particularly in tackling unmet needs in cancer care such as brain cancer treatments. This transition is not only a testament to Perreault’s visionary approach but also underlines Kiyatec’s dedication to improving patient outcomes and leading the charge in the evolving landscape of precision oncology. The continuity of leadership, with Gevaert remaining on the board, ensures that Kiyatec retains its foundational expertise while propelling forward with fresh strategic insights. As the company continues to develop and expand the applications of its 3D cell culture technology, the industry and patients alike await the transformative impact it promises in the field of cancer care.
